Brief: Medesis Pharma Plans To Accelerate Development Of Three Anti-Nuclear Drugs

Medesis Pharma SA

05/04/2022 07:51

April 5 (Reuters) - Medesis Pharma SA  ALMDP.PA :
    * REG-MEDESIS PHARMA WISHES TO ACCELERATE THE DEVELOPMENT OF
ITS
ANTINUCLEAR PRODUCTS AND PROVIDES AN UPDATE ON ITS STRATEGY
    * THREE DRUGS ARE SPECIFICALLY INTENDED FOR TREATMENT OF
LARGE
POPULATIONS CONTAMINATED OR IRRADIATED AFTER A CIVIL OR MILITARY
NUCLEAR ACCIDENT
    * TO DATE, THERE IS NO SUITABLE TREATMENT FOR A SERIOUS
NUCLEAR
ACCIDENT
    * THREE PRODUCTS ARE AT HEART OF ISSUES WITH TRAGIC
INTERNATIONAL
SITUATION IN UKRAINE, RAISING POSSIBILITY OF NUCLEAR WAR
    * FUNDING REQUESTS FOR THESE 3 PROGRAMS HAVE BEEN SUBMITTED
BY
MEDESIS PHARMA TO THE FRENCH DEFENSE INNOVATION AGENCY
    * MEDESIS PHARMA'S THREE DRUG CANDIDATES WERE DEVELOPED IN
COLLABORATION WITH FRENCH ATOMIC ENERGY COMMISSION (LRT-CEA)

Source text for Eikon:  ID:nGNEwH89c 
Further company coverage:  ALMDP.PA 

 (Gdansk Newsroom)